Reduction of breast density with 4-hydroxy tamoxifen
A method of treatment comprises administering 4-hydroxy tamoxifen percutaneously to a patient having dense breast tissue. The 4-hydroxy tamoxifen may be formulated in a hydroalcoholic gel or an alcoholic solution.
1. A method of reducing breast density, comprising percutaneously administering, to a patient having class III or class IV dense breast composition, a pharmaceutical composition for percutaneous administration comprising 4-hydroxy tamoxifen and isopropyl myristate.
2. A method according to claim 1 , wherein said dense breast tissue is diffuse.
3. A method according to claim 1 , wherein said dense breast tissue is nodular.
4. A method according to claim 1 , wherein said 4-hydroxy tamoxifen is a blend of trans and cis isomers.
5. A method according to claim 1 , wherein said 4-hydroxy tamoxifen is a trans isomer.
6. A method according to claim 1 , wherein greater than about 0.5 mg/breast of said 4-hydroxy tamoxifen is administered per day.
7. A method according to claim 1 , wherein greater than about 0.75 mg/breast of said 4-hydroxy tamoxifen is administered per day.
8. A method according to claim 1 , wherein greater than about 1.0 mg/breast of said 4-hydroxy tamoxifen is administered per day.
9. A method according to claim 1 , wherein said pharmaceutical composition comprises a hydroalcoholic gel.
10. A method according to claim 9 , wherein said hydroalcoholic gel comprises ethyl alcohol, isopropyl myristate, and hydroxypropylcellulose.
11. A method according to claim 1 , wherein said pharmaceutical composition comprises an alcoholic solution.
12. A method of improving mammographic sensitivity that comprises performing the method of claim 1 , then performing mammography on said patient.
13. A method according to claim 12 , wherein said 4-hydroxy tamoxifen is a blend of trans and cis isomers.
14. A method according to claim 12 , wherein said 4-hydroxy tamoxifen is a trans isomer.
15. A method according to claim 12 , wherein greater than about 0.5 mg/breast of said 4-hydroxy tamoxifen has been administered per day.
16. A method according to claim 12 , wherein greater than about 0.75 mg/breast of said 4-hydroxy tamoxifen has been administered per day.
17. A method according to claim 12 , wherein greater than about 1.0 mg/breast of said 4-hydroxy tamoxifen has been administered per day.
18. A method according to claim 12 , wherein said pharmaceutical composition comprises a hydroalcoholic gel.
19. A method according to claim 18 , wherein said hydroalcoholic gel comprises ethyl alcohol, isopropyl myristate, and hydroxypropylcellulose.
20. A method according to claim 9 , wherein said pharmaceutical composition comprises 4-hydroxy tamoxifen, ethyl alcohol, isopropyl myristate, hydroxypropylcellulose and phosphate buffer.
21. A method according to claim 9 , wherein said pharmaceutical composition comprises from about 0.001 g to about 1.0 g of 4-hydroxy tamoxifen per 100 g gel.
22. A method according to claim 21 , wherein said pharmaceutical composition comprises from about 0.01 g to about 0.1 g of 4-hydroxy tamoxifen per 100 g gel.
23. A method according to claim 18 , wherein said pharmaceutical composition comprises 4-hydroxy tamoxifen, ethyl alcohol, isopropyl myristate, hydroxypropylcellulose and phosphate buffer.
24. A method according to claim 18 , wherein said pharmaceutical composition comprises from about 0.00 1 g to about 1.0 g of 4-hydroxy tamoxifen per 100 g gel.
25. A method according to claim 24 , wherein said pharmaceutical composition comprises from about 0.01 g to about 0.1 g of 4-hydroxy tamoxifen per 100 g gel.